> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# State Street Holds 5.6% Of Recursion Pharmaceuticals On A Passive Basis
- URL: https://www.bullished.co/state-street-holds-5-6-of-recursion-pharmaceuticals-on-a-passive-basis-06ee1182/
- Published: 2026-11-10T15:19:32.000Z
- Updated: 2026-11-10T15:19:32.000Z
- Description: The position covered 30,001,137 common shares as of September 30, 2026, rather than a stake bought to influence control.
- Author: Matteo Parrino
- Tags: SEC Filings, RXRX, Industry: Healthcare

State Street reported a [5.6% stake](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000711/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [Recursion Pharmaceuticals](https://www.bullished.co/tag/rxrx/), a clinical-stage drug developer using artificial intelligence and automated laboratories, in a passive ownership disclosure filed Tuesday. The position covered 30,001,137 common shares as of September 30, 2026.

## Passive Ownership, Shared Voting Power

State Street certified that it bought and held the securities as part of its ordinary business, rather than with the aim or effect of changing Recursion's control.

Its [shared voting power](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000711/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) covered 28,700,743 shares. State Street reported sole voting power of zero and shared power to dispose of all 30,001,137 shares.

## AI Laboratories And Drug Partnerships

Recursion's Recursion Operating System spans the generation of biological data, small-molecule design and clinical-trial work. Its automated laboratories can conduct more than 2 million experiments a week, according to its annual report for 2025.

That report described an internal pipeline of five clinical and two preclinical programs focused on oncology and rare diseases, including REC-4881 for familial adenomatous polyposis.

Recursion also works with Roche and Genentech, Sanofi, Bayer and Merck KGaA on funded discovery efforts in oncology, neuroscience and immunology. Its annual report said partner upfront and milestone payments had exceeded $500 million.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — STATE STREET CORPORATION re: RECURSION PHARMACEUTICALS INC (RXRX)](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000711/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR

### More on Recursion Pharmaceuticals

- [Recursion Says Oral FAP Drug Shrank Upper-Gut Polyps In 92% Of Patients](https://www.bullished.co/recursion-says-oral-fap-drug-shrank-upper-gut-polyps-in-92-of-patients-7658095a/)
- [Recursion Cuts Its Tempus Data Fee To $14.0 Million A Year, But Loses The Right To Walk Away](https://www.bullished.co/recursion-cuts-its-tempus-data-fee-to-14-0-million-a-year-but-loses-the-right-to-walk-away-d7bf91db/)
- [Recursion Cuts Quarterly Loss To $119.0 Million, Sees Cash Lasting Into 2029](https://www.bullished.co/recursion-cuts-quarterly-loss-to-119-0-million-sees-cash-lasting-into-2029-d85dbb77/)

[All Recursion Pharmaceuticals (RXRX) coverage →](https://www.bullished.co/tag/rxrx/)